AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma

Gastroenterology

Volumn 117, Issue 6, 1999, Pages 1464-1484

  Dimagno, E P ^a   Reber, H A ^a   Tempero, M A ^a  

^a AGA National Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLACINOMYCIN; ANTINEOPLASTIC AGENT; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; CYTARABINE; DIAZIQUONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LOMUSTINE; MAYTANSINE; MELPHALAN; METHOTREXATE; MITOGUAZONE; MITOMYCIN; MITOXANTRONE; RECOMBINANT ALPHA INTERFERON; SOMATOSTATIN; SPARFOSIC ACID; SPIROGERMANIUM; STREPTOZOCIN; TAMOXIFEN; TRIAZINATE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; HUMAN; PALLIATIVE THERAPY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE;

EID: 0032760453     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(99)70298-2     Document Type: Article

References (195)

1. SL Parker T Tong S Bolden PA. Wingo Cancer statistics 1996 CA Cancer J Clin 46 1996 5 27
2. A Riela AR Zinsmeister LJ Melton III LH Weiland EP. DiMagno Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988 Mayo Clin Proc 67 1992 645 839
3. JE Niederhuber MF Brennan HR. Menck The National Cancer Data Base report on pancreatic cancer Cancer 76 1995 1671 1677
4. AB Lowenfels P Maisonneuve EP DiMagno Y Elitsur LK Gates Jr J Perrault DC Whitcomb International Hereditary Pancreatitis Study Group Hereditary pancreatitis and the risk of pancreatic cancer J Natl Cancer Inst 89 1997 442 446
5. DC Whitcomb MC Gorry RA Preston W Furey MJ Sossenheimer CD Ulrich SP Martin JK Gates Jr ST Amann PP Toskes R Liddle K McGrath G Uomo JC Post GD. Ehrlich Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene Nat Genet 14 1996 141 145
6. MC Gorry D Gabbaizedeh W Furey LK Gates Jr RA Preston CE Aston Y Zhang C Ulrich GD Ehrlich DC. Whitcome Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis Gastroenterology 113 1997 1063 1068
7. AB Lowenfels P Maisonneuve G Cavallini RW Ammann PG Lankisch JR Andersen EP DiMagno A Andren-Sandberg L Domellof International Pancreatitis Study Group Pancreatitis and the risk of pancreatic cancer N Engl J Med 328 1993 1433 1437
8. P Bansal A. Sonnenberg Pancreatitis is a risk factor for pancreatic cancer Gastroenterology 109 1995 247 251
9. BM Karlson A Ekbom S Josefsson JK McLaughlin JF Fraumeni Jr O. Nyren The risk of pancreatic cancer following pancreatitis: an association due to confounding? Gastroenterology 113 1997 587 592
10. EV Loftus Jr BA Olivares-Pakzad KP Batts MC Adkins DH Stephens EP DiMagno DG Kelly LJ Miller RK Pearson JE Clain BT Petersen MB Farnell MG Sarr GB Thompson JA van Heerden DM Nagorney JH Donohue Intraductal papillary-mucinous tumors of the pancreas—clinicopathologic features, outcome, and nomenclature Gastroenterology 110 1996 1909 1918
11. K Ohashi K. Takagi ERCP and imaging diagnosis of pancreatic cancer [in Japanese; English abstract] Gastrointest Endosc 77 1997 1493 1495
12. JA Rivera C Fernandez-del Castillo M Pins CC Compton KB Lewandrowski DW Rattner AL. Warshaw Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity Ann Surg 225 1997 637 644
13. RK McDowell GS Gazelle BL Murphy GW Boland WW Mayo-Smith AL Warshaw PR. Mueller Mucinous ductal ectasia of the pancreas J Comput Assist Tomogr 21 1997 383 388
14. F Sessa E Solcia C Capella M Bonato A Scarpa G Zamboni NS Pellegata GN Ranzani F Rickaert G. Kloppel Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients Virchows Arch 425 1994 357 367
15. L Gullo R Pezzilli AM Morselli-Labate Italian Pancreatic Cancer Study Group Diabetes and the risk of pancreatic cancer N Engl J Med 331 1994 81 84
16. J Permert J Larsson GT Westermark MK Herrington L Christmanson PM Pour P Westermark TE. Adrian Islet amyloid polypeptide in patients with pancreatic cancer and diabetes N Engl J Med 330 1994 313 318
17. SS Schwarts A Zeidler AR Moossa SF Kuku AH. Rubenstein A prospective study of glucose intolerance, insulin, C-peptide, and glucagon in patients with pancreatic carcinoma Am J Dig Dis 23 d1978 1107 1114
18. J Everhart D. Wright Diabetes mellitus as a risk factor for pancreatic cancer JAMA 273 1995 1605 1609
19. P Ghadirian P Boyle A Simard J Baillargeon P Maisonneuve C. Perret Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada Int J Pancreatol 10 1991 183 196
20. HT Lynch ML Fitzsimmons TC Smyrk SJ Lanspa P Watson J McClellan JF. Lynch Familial pancreatic cancer: clinicopathologic study of 18 nuclear families Am J Gastroenterol 85 1990 54 60
21. FM Giardiello GJ Offerhaus DH Lee AJ Krush AC Tersmette SV Booker NC Kelley SR. Hamilton Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis Gut 34 1993 1394 1396
22. HT Lynch RM. Fusaro Pancreatic cancer and the familial atypical multiple mole melanoma Pancreas 6 1991 127 131
23. AM Goldstein MC Fraser JP Struewing CJ Hussussian K Ranade DP Zametkin LS Fontaine SM Organic NC Dracopoli WH Clark Jr MA. Tucker Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations N Engl J Med 333 1995 970 974
24. C Patrianakos D. Hoffman Chemical studies on tobacco smoke LXIV. On the analysis of aromatic amines in cigarette smoke J Anal Toxicol 3 1979 150 159
25. TM Mack MC Yu R Hanisch BE. Henderson Pancreas cancer and smoking, beverage consumption and past medical history J Natl Cancer Inst 76 1986 49 60
26. RT Falk LW Pickle ET Fontham P Correa JF. Fraumeni Life-style risk factors for pancreatic cancer in Louisiana: a case-control study Am J Epidemiol 128 1988 324 336
27. PK Mills L Beeson DE Abbey GE Fraser RL. Phillips Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists Cancer 61 1988 2578 2585
28. SE Norell A Ahlbom R Erwald G Jacobson I Lindberg-Navier R Olin B Tornberg KL Wiechel Diet and pancreatic cancer: a case-control study Am J Epidemiol 124 1986 894 902
29. T. Sugimura Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process Mutat Res 150 1985 33 41
30. T Sugimura S. Sato Mutagens-carcinogens in foods Cancer Res 43 1983 2415s 2421s
31. MJ Appel RA. Woutersen Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine-treated rats Br J Cancer 73 1996 36 43
32. MJ Appel RA Woutersen Effects of dietary fish oil (maxEPA) on N -nitrosobis(2-oxopropyl)amine (BOP)-induced pancreatic carcinogenesis in hamsters Cancer Lett 94 1995 179 189
33. TM. Mack Pancreas D Schottenfeld JF Fraumeni Jr Cancer epidemiology and prevention. 1982 Saunders Philadelphia 638 667
34. RT Falk LW Pickle ET Fontham P Correa A Morse V Chen JF Fraumeni Jr. Occupation and pancreatic cancer risk in Louisiana Am J Intern Med 18 1990 565 576
35. KA Steinmetz JD. Potter Vegetables, fruit, and cancer. I. Epidemiology Cancer Causes Control 2 1991 237 325
36. KA Steinmetz JD. Potter Vegetables, fruit, and cancer. II. Mechanisms Cancer Causes Control 2 1991 427 442
37. MH Kalser J Barkin JM. MacIntyre Pancreatic cancer. Assessment of prognosis by clinical presentation Cancer 56 1985 397 402
38. A Mannell JA van Heerden LH Weiland DM. Ilstrup Factors influencing survival after resection for ductal adenocarcinoma of the pancreas Ann Surg 203 1986 403 407
39. RS Metzgar HL. Asch Antigens of human pancreatic adenocarcinomas: their role in diagnosis and therapy Pancreas 3 1988 352 371
40. MR Posner RJ. Mayer The use of serologic tumor markers in gastrointestinal malignancies Hematol Oncol Clin North Am 8 1994 533 552
41. DK Pleskow HJ Berger J Gyves E Allen A McLean DK. Podolsky Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer Ann Intern Med 110 1989 704 709
42. F Safi W Schlosser S Falkenreck HG. Beger CA 19-9 serum course and prognosis of pancreatic cancer Int J Pancreatol 20 1996 155 161
43. MB Albert WM Steinberg JP. Henry Elevated serum levels of tumor marker CA19-9 in acute cholangitis Dig Dis Sci 33 1988 1223 1225
44. P Westermark E Wilander GT Westermark KH. Johnson Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals Diabetologia 32 1987 887 892
45. R Sowa T Sanke J Hirayama H Tabata H Furuta S Nishimura K. Nanjo Islet amyloid polypeptide amide causes insulin resistance in vivo in dogs Diabetologia 33 1990 118 120
46. WT Chance A Balasubramaniam FS Zhang SJ Wimalawansa JE. Fischer Anorexia following the intrahypothalamic administration of amylin Brain Res 539 1991 352 354
47. C Almoguera D Shibata K Forrester J Martin N Arnheim M. Perucho Most carcinomas of the exocrine pancreas contain mutant c-Kras genes Cell 53 1988 549 559
48. RH Hrubran AOM van Mansfeld GJA Offerhaus DHJ van Weering DC Allison SN Goodman TW Kensler KK Bose JL Cameron JL. Bos K-ras oncogene activation in adenocarcinomas of the human pancreas: a study of 82 carcinomas using a combination of mutant-rich PCR analysis and allele oligonucleotide hybridization Am J Pathol 143 1993 545 554
49. NR Lemoine S Jain C Hughes SL Staddon B Maillet G. Kloeppel K-ras oncogene activation in preinvasive pancreatic cancer Gastroenterology 102 1992 230 236
50. S Pellagata F Sessa B Renault M Bonato BE Leone E Solcia RN. Ranzani K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions Cancer Res 54 1994 1156 1160
51. MS Redston C Caldas AB Seymour RH Hruban L da Costa CH Yeo SE. Kern p53 mutations in pancreatic carcinoma and evidence of common involvement in homopolymer tracts in DNA microdeletions Cancer Res 54 1994 3025 3033
52. MW Hohne ME Halatsch GF Dahl RJ. Winel Frequent loss of expression of the potential tumor-suppressor gene DCC in ductal pancreatic adenocarcinoma Cancer Res 52 1992 2616 2619
53. B Simon R Weinel Mw Hohne J Watz J Schmidt G Kortner R. Arnold Frequent alterations of the tumor suppressor genes p53 and DCC in Human pancreatic carcinoma Gastroenterology 106 1994 1645 1651
54. C Caldas SA Hahn LT da Costa MS Redston M Shutte AB Seymour CL Weinstein RH Hruban CJ Yeo SE. Kern Frequent somatic mutations and homozygous deletions of the MTS1 gene in pancreatic adenocarcinoma Nat Genet 8 1994 27 32
55. Q Liu YX Yan M McClure H Nakagawa F Fufimera AK. Rustgi MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines Oncogene 10 1995 619 622
56. MV Ponce-Castaneda MH Lee E Latres K Polyak L Lacombe K Montgomery S Mathew K Krauter J Sheinfeld J Massague C. Cordon-Cardo p27Kipl: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors Cancer Res 55 1995 1211 1214
57. M Naumann N Savitskaia C Ilert A Schramm H Kalthoff W. Schmiegel Frequent codelation of p16/MTSI and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors Gastroenterology 110 1996 1215 1224
58. H Watanabe N Sawabu H Ohta Y Saatomura O Yamakawa Y Motoo T Okai H Takahashi T. Wakabayashi Identification of K-ras oncogene mutations in pure pancreatic juice of patients with ductal pancreatic cancers Jpn J Cancer Res 84 1993 961 965
59. M Tada M Omata S Kawai H Saisho M Ohto RK Saikki JJ. Sninsky Detection of ras gene in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma Cancer Res 53 1993 2472 2474
60. H Kondo K Sugano N Fukayama A Kyogoku H Nose K Shimada H Ojkura A Ohtsu S Yoshida Y. Shimosato Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma Cancer 73 1994 1589 1594
61. P Bethelemy M Bouisson J Escourrou N Vaysse JL Rumeau L. Pradayrol Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer Ann Intern Med 123 1995 188 191
62. H Iguchi K Sugano N Fukayama H Ohkura K Sadamoto K Ohkoshi Y Seo H Tomoda A Funakoshi H. Wakasugi Analysis of the K-ras codon mutations in duodenal juice: possible application of a secretin test as a diagnostic tool for pancreatic cancers Gastroenterology 110 1996 221 226
63. C Caldas SA Hanh RH Hrubran MS Redston CJ Yeo SE. Kern Detection of K-ras mutation in stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia Cancer Res 54 1994 3568 3573
64. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis Cancer Res 55 1995 4264 4267
65. N Furuya S Kawa T Akamatsu K. Furihata Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice Gastroenterology 113 1997 595 598
66. M Tada M Ohashi Y Shiratori T Okudaira Y Komatsu T Dawabe H Yoshida R Machinami K Kishi M. Omata Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease Gastroenterology 110 1996 227 231
67. JA Rivera C Fernandez-del Castillo CJN Rall F Graeme-Cook P Shu N Lakey R Tepper DW Rattner AL Warshaw AK. Rustgi Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia Surgery 121 1997 42 49
68. MF Muller C Meyenberger P Bertschinger R Schaer B. Marincek Pancreatic tumors: evaluation with endoscopic US, CT and MR imaging Radiology 190 1994 745 751
69. DA Bluemke JL Cameron RH Hruban Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation Radiology 197 1995 381 385
70. P Legman O Vignaus B Dousser A-P Baraza L Palazzo I Dumontier J Coste A Louvel G Rouseau D Couturier A. Bonnin Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography Am J Radiol 170 1998 1315 1322
71. DS Lu HA Reber RM Krasny BM Kadell J. Sayre Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT Am J Radiol 168 1997 1439 1443
72. RC Semelka NL Kelekis PL Molina TJ Sharp B. Calvo Pancreatic masses with inconclusive findings on spiral CT: is there a role for MRI? J Magn Reson Imaging 6 1996 585 588
73. T Rösch R Lorenz C Braig S Feurbach JR Siewert V Schudziarra M Classen Endoscopic ultrasound in pancreatic tumor diagnosis Gastrointest Endosc 37 1991 342 347
74. T Rösch C Braig T Gain S Feurbach JR Siewert V Schudziarra M Classen Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography and angiography Gastroenterology 102 1992 188 189
75. T Rösch R Lorenz C Braig H Dancygier M Classen Endoscopic ultrasound in small pancreatic tumors Z Gastroenterol 29 1991 110 115
76. T Rösch CJ Lightdale JF Botet GA Boyce MV Sivak Jr K Yasuda N Heyder L Palazzo H Dancygier V Schusdziarra M Classen Localization of pancreatic endocrine tumors by endoscopic ultrasonography N Engl J Med 326 1992 1721 1726
77. T Rösch R Lorenz C Braig M Classen Endoscopic ultrasonography in diagnosis and staging of pancreatic and biliary tumors Endoscopy 24 1992 304 308
78. KJ Chang P Nguyen RA Erickson TE Durbin KD. Katz The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma Gastrointest Endosc 45 1997 387 393
79. MJ Wiersema P Vilmann M Giovanni KJ Chang LM. Wiersma Endosongraphy-guided fine needle aspiration biopsy: diagnostic accuracy and complication assessment Gastroenterology 112 1997 1087 1095
80. PC Freeny LW Traverso JA. Ryan Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography Am J Surg 165 1993 600 606
81. M Trede B Rumstadt K Wendl J Gaa K Tesdal K-J Lehmann H-J Meier-Willerson P Pescatore J. Schmoll Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors Ann Surg 226 1997 393 407
82. AL Warshaw Z Gu J Wittenberg AC. Waltman Preoperative staging and assessment of resectability of pancreatic cancer Arch Surg 125 1990 230 233
83. KC Conlon E Dougherty DS Klimstra DG Coit ADM Turnbull MF. Brennan The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy Ann Surg 223 1996 134 140
84. Conlon KC, Minnard EA. The value of laparoscopic staging in upper gastrointestinal malignancy. Oncologist (in press).
85. S Shimi S Banting A. Cuschieri Laparoscopy in the management of pancreatic cancer: endoscopic cholecystojejunostomy for advanced disease Br J Surg 79 1992 317 319
86. M Rhodes L Nathanson G. Fielding Laparoscopic biliary and gastric bypass: a useful adjunct in the treatment of carcinoma of the pancreas Gut 36 1995 778 780
87. B Gloor KE Todd HA. Reber Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach Cancer 79 1997 1780 1786
88. HA Pitt AS Gomes JF Lois LL Mann LS Deutsch WP Longmire Jr. Does preoperative percutaneous biliar y drainage reduce operative risk or increase hospital cost? Ann Surg 201 1985 545 553
89. MJ Heslin AD Brooks SN Hochwald LE Harrison LH Blumgart MF. Brennan A preoperative biliar y stent is associated with increased complications after pancreatoduodenectomy Arch Surg 133 1998 149 154
90. SP Povoski MS Karpeh KC Conlon LH Blumgart MF. Brennan Effect of preoperative biliar y drainage on postoperative outcome following pancreatoduodenectomy Ann Surg 1999 (in press)
91. MP Spencer MG Sarr DM. Nagorney Radical pancreatectomy for pancreatic cancer in the elderly. Is it safe and justified? Ann Surg 212 1990 140 143
92. KE Todd J Lane HA. Reber Questions most commonly asked regarding pancreatic cancer Prob Gen Surg 141 1997 27 32
93. HA. Reber Small pancreatic tumors: is size and indication of curability? J Hepatobiliary Pancreat Surg 2 1995 384 386
94. H. Reber The classic Whipple operation for pancreatic cancer Dig Surg 11 1994 387 389
95. HA. Pitt Curative treatment for pancreatic neoplasms. Standard resection Surg Clin North Am 75 1995 891 904
96. CJ Yeo JL Cameron KD Lillemoe JV Sitzmann RH Hruban SN Goodman WC Dooley J Coleman HA. Pitt Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients Ann Surg 221 1995 721 733
97. HA Reber SW Ashley D. McFadden Curative treatment for pancreatic neoplasms Surg Clin North Am 75 1995 905 912
98. M Trede DC. Carter Preoperative assessment and indications for operation in chronic pancreatitis M Trede DC Carter Surgery of the pancreas 1993 Churchill Livingstone Edinburgh 283 298
99. M Trede G Schwall HD. Saeger Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality Ann Surg 211 1990 447 458
100. M Trede G Schwall HD. Saeger Survival after pancreatoduodenectomy Ann Surg 211 1990 447 458
101. JL Cameron HA Pitt CJ Yeo KD Lillemoe HS Kaufman J. Coleman One hundred and forty-five consecutive pancreatoduodenectomies without mortality Ann Surg 217 1993 430 438
102. MG Patti CA Pelligrini LW. Way Gastric emptying and small bowel transit of solid food after pylorus-preserving pancreaticoduodenectomy Arch Surg 122 1987 528 532
103. AS Fink LR DeSouza EA Mayer R Hawkins WP Longmire Jr. Long-term evaluation of pylorus preservation during pancreaticoduodenectomy World J Surg 12 1988 663 670
104. JD Roder HJ Stein W Huttl JR. Siewert Pylorus-preserving versus standard pancreaticoduodenectomy: an analysis of 110 pancreatic and periampullary carcinomas Br J Surg 79 1992 152 155
105. W. Kozuschek HB Reith Lessons learned from experience with pancreatoduodenectomy for pancreatic cancer: German experience from Bochum LW Traverso Problems in general surgery—pancreatic cancer 1997 Lippincott-Raven Philadelphia 67 74
106. W Kozuschek HB Reith H Waleczek W Haarman M Edelmann D. Sonntag A comparison of the standard Whipple procedure and the pylorus preserving pancreatoduodenectomy J Am Coll Surg 178 1994 443 458
107. O Ishikawa H Ohhigashi Y Sasaki T Kabuto I Fukuda H Furukawa S Imaoka T. Iwanaga Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head Ann Surg 208 1988 215 220
108. S Takahashi Y Ogata H Miyazaki D Maeda S Murai K Yamataka T. Tsuzuki Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations World J Surg 19 1995 653 660
109. HA Reber B. Gloor Radical pancreatectomy Surg Oncol Clin North Am 7 1998 157 164
110. F Hanyu M Suzuki T. Imaizumi Whipple operation for pancreatic carcinoma: Japanese experience HG Beger MW Buchler P Malfertheiner Standard in pancreatic surgery 1993 Springer-Verlag Heidelberg, Germany 646 653
111. TA Gordon GP Burleyson JM Tielschi JL. Cameron The effects of regionalization on cost and outcome for one general high-risk surgical procedure Ann Surg 221 1995 43 49
112. RE Glasgow SJ. Mulvihill Hospital volume influences outcome in patients undergoing pancreatic resection for cancer West J Med 165 1996 294 300
113. EH Livingston ML Welton HA. Reber The United States' experience with surgery for pancreatic cancer Int J Pancreatol 9 1991 153 157
114. SS Nitecki MG Sarr TV Colby JA. van Heerden Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg 221 1994 59 66
115. R Tsuchiya T Noda N Harada T Miyamoto T Tomioka K Yamamoto T Yamaguchi K Izawa T Tsunoda R Yoshino T. Eto Collective review of small carcinomas of the pancreas Ann Surg 203 1986 77 81
116. H. Onoyma T Kamigaki M Yamamoto Y. Saitoh Treatment and present status of pancreatic cancer Jpn J Cancer Chemother 19 1992 2304 2310
117. JL Cameron DW Crist JV Stizmann RH Hruban JK Boitnott AJ Seidler J. Coleman Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer Am J Surg 161 1991 120 125
118. A Mannell JA van Heerden LH Weiland DM. Ilstrup Factors influencing survival after resection of ductal adenocarcinoma of the pancreas Ann Surg 203 1986 403 407
119. TC Bottger S Storkel S Wellek M Stockle T. Junginger Factors influencing survival after resection of pancreatic cancer: a DNA analysis and histomorphologic study Cancer 73 1994 63 73
120. DC Allison KK Bose RH Hruban S Piantadosi WC Dooley JK Boitnott JL. Cameron Pancreatic cancer cell DNA content correlates with long-term survival after pancreaticoduodenectomy Ann Surg 214 1991 648 656
121. RJ Geer MF. Brennan Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am J Surg 165 1993 68 73
122. CJ Yeo JL Cameron KD Lillemoe JV Sitzmann RH Hruban SN Goodman WC Dooley J Coleman HA. Pitt Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients Ann Surg 221 1995 721 731
123. M Kobari M Sunamura O Ohashi Y Saitoh T Yusa S. Matsuno Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas J Am Coll Surg 182 1996 24 32
124. AL Warshaw C Fernández-del Pancreatic carcinoma N Engl J Med 326 1992 455 465
125. SM Singh WP Longmire Jr HA. Reber Surgical palliation for pancreatic cancer. The UCLA experience Ann Surg 212 1990 132 139
126. P Watanapa RCN. Williamson Surgical palliation for pancreatic cancer: developments during the past two decades Br J Surg 79 1992 8 20
127. PD DeRooij A Rogatko MF. Brennan Evaluation of palliative surgical procedures in unresectable pancreatic cancer Br J Surg 78 1991 1053 1058
128. AG Speer PB Cotton RC Russell RR Mason AR Hatfield JW Leung KD MacRae J Houghton CA. Lennon Randomized trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice Lancet 2 1987 57 62
129. F Prat O Chapat B Ducto T Ponchon G Pelletier J Fritsch AD Choury C. Buffet A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct Gastrointest Endosc 47 1998 1 7
130. JS Barkin RI Goldberg GN Sfakianakis J. Levi Pancreatic carcinoma is associated with delayed gastric emptying Dig Dis Sci 31 1986 265 267
131. RM Soetikno DR Lichtenstein J Vandervoort RCK Wong AD Roston A Slivka H Montes DL. Carr-Locke Palliation of malignant gastric outlet obstruction using an endoscopically placed Wallstent Gastrointest Endosc 47 1998 267 270
132. AW Nevitt F Vida RA Kozarek LW Traverso SL. Raltz Expandable metallic prostheses for malignant obstructions of gastric outlet and proximal small bowel Gastrointest Endosc 47 1998 271 276
133. KD Lillimoe JL Cameron HS Kaufman CJ Yeo HA Pitt PK. Sauter Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A Prospective randomized trial Ann Surg 217 1993 447 455
134. E Polati G Finco L Gottin C Bassi P Pederzoli S. Ischia Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer Br J Surg 85 1998 199 201
135. M Kawamata K Ishitani K Ishikawa H Sasaki K Ota K Omote A. Namiki Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain Pain 64 1996 597 602
136. DP Kelsen RK Portenoy HT Thaler D Niedzwiecki SD Passik Y Tao W Banks MF Brennan KM. Foley Pain and depression in patients with newly diagnosed pancreas cancer J Clin Oncol 13 1995 748 755
137. SD Passik WS. Breithart Depression in patients with pancreatic carcinoma: diagnostic and treatment issues Cancer 78 1996 615 626
138. MM Perez AD Newcomer CG Moertel VLW Go EP. DiMagno Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer Cancer 52 1983 346 352
139. MJ Bruno EB Haverkort GP Tijssen GN Tytgat DJ. van Leeuwen Placebo controlled trial of enteric coated pancreatin micro-sphere treatment in patients with unresectable cancer of the pancreatic head region Gut 42 1998 92 96
140. EP DiMagno J-R Malagelada VLW. Go The relationships between pancreatic ductal obstruction and pancreatic secretion in man Mayo Clin Proc 54 1979 157 162
141. L Guarner R Rodriguez F Guarner J-R. Malagelada Fate of oral enzymes in pancreatic insufficiency Gut 34 1993 708 712
142. PC. Freeny Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma Radiol Clin North Am 27 1989 121 128
143. ML Rothenberg JL Abbruzzese M Moore RK Portenoy JM Robertson HJ. Wanebo A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma Cancer 78 1996 627 632
144. JD. Ahlgren Chemotherapy for pancreatic carcinoma Cancer 78 1996 654 663
145. J Glenn WM Steinberg SH Kurtzman SM Steinberg WF. Sindelar Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas J Clin Oncol 6 1988 462 468
146. H Ishii S Okada T Sato H Wakasugi H Saisho J Furese O Ishikawa S Matsuno S. Yokoyama CA19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer Hepatogastroenterology 44 1997 279 283
147. B Glimelius K Hoffman PO Sjödén G Jacobsson H Sellström LK Enander T Linné C Svensson Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 1996 593 600
148. ML. Rothenberg New developments in chemotherapy for patients with advanced pancreatic cancer Oncol Hunt 10 1996 18 22
149. ML Rothenberg MJ Moore MC Cripps JS Andersen RK Portenoy HA Burris MR Green PG Tarassoff TD Brown ES Casper AM Storniolo DD. Von Hoff A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer Ann Oncol 7 1996 347 353
150. HA Burris MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD. Von Hoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
151. D. Kelsen The use of chemotherapy in the treatment of advanced gastric and pancreas cancer Semin Oncol 4 1994 172 174
152. D Fennelly DP. Kelsen The role of chemotherapy in the treatment of adenocarcinoma of the pancreas Hepatogastroenterology 43 1996 356 362
153. H Riess P Htun J Loffel D. Huhn Chemotherapy for patients with adenocarcinoma of the pancreas: recent results Cancer Res 142 1996 415 424
154. JJ Lokich JD Ahlgren JJ Gullo JA Philips JG. Fryer A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A mid-Atlantic Oncology Program Study J Clin Oncol 7 1989 425 432
155. W Scheithauer F Pfeffel G Kornek A Marczell C Wiltschke J. Funovics A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas Cancer 70 1992 1864 1866
156. MA. Tempero Chemotherapy of pancreatic cancer H Reber Advances in pancreatic cancer 1998 Humana Totowa, NJ 265 280
157. RM Bukowski LP Schacter CW Groppe JS Hewlett JK Weick RB. Livingston Phase II trial of 5-fluorouracil, adriamycin, mitomycin-C and streptozotocin (FAM-S) in pancreatic carcinoma Cancer 50 1982 197 200
158. FP Smith DF Hoth BF Levin DA Karlin JS MacDonald PV Woolley PS. Schein 5-Fluorouracil, adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas Cancer 46 1980 2014 2018
159. RG Wiggans PV Woolley JS MacDonald T Smythe W Ueno PS. Schein Phase II trial of streptozotocin, mitomycin C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer Cancer 41 1978 387 391
160. J Dougherty D Kelsen N Kemeny G Magill J Bottet D. Niedzwiecki Advanced pancreatic cancer: a phase I-II trial of cisplatin, high dose cytarabine and caffeine J Natl Cancer Inst 81 1989 1735 1738
161. MW Oster R Gray L Panasci MC. Perry Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM) Cancer 57 1986 29 33
162. Gastrointestinal Tumor Study Group Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil J Clin Oncol 4 1986 1794 1798
163. SA Cullinan CG Moertel TR Fleming JR Rubin JE Krook LK Everson HE Windschitl DI Twito RF Marschke JF Foley DM Pfeifle JF. Barlow A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma JAMA 253 1985 2061 2067
164. KR Palmer M Kerr G Knowles A Cull DC Carter CF. Leonard Chemotherapy prolongs survival in inoperable pancreatic carcinoma Br J Surg 81 1994 882 885
165. CN Mallinson MO Rake JB Cocking CA Fox MT Cwynarski BL Diffey GA Jackson J Hanley VJ. Wass Chemotherapy in pancreatic cancer: results from a controlled, prospective, randomised, multicentre trial Br Med J 281 1980 1589 1591
166. S Cullinan CG Moertel HS Wieand AJ Schutt JE Krook JF Foley BD Norris CG Kardinal LK Tschetter JF. Barlow A phase II trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin Cancer 65 1990 2207 2212
167. M Tempero P Leichner G Dalrymple K Harrison S Augustine J Schlom J Anderson J Wisecarver D. Colcher High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial J Clin Oncol 4 1997 1518 1528
168. Gastrointestinal Tumor Study Group Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer Cancer 58 1987 2006 2010
169. JP Hoffman JL Weese LJ Solin P Agarwal R Scher AR Paul S Litwin P Watts BL. Eisenberg A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma Am Surg 59 1993 772 781
170. JM Jessup G Steele RJ Mayer M Posner P Busse B Cady M Stone R Jenkins R. Osteen Neoadjuvant therapy for unresectable pancreatic adenocarcinoma Arch Surg 128 1993 559 564
171. DB Evans TA Rich DR Byrd KR Cleary JH Connelly B. Levin Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg 127 1992 1335 1339
172. FR Spitz JL Abbruzzese JE Lee PW Pisters AM Lowy CJ Fenoglio KR Cleary NA Janjan MS Goswitz TA Rich DB. Evans Preoperative and postoperative chemoradiation strategies in patients with pancreaticoduodenectomy for adenocarcinoma of the pancreas J Clin Oncol 15 1997 928 937
173. CG Moertel S Frytak RG Hahn MJ O'Connell RJ Reitemeier J Rubin AJ Schutt LH Weiland DS Childs MA Holbrook PT Lavin E Livstone H Spiro A Knowlton M Kalser J Barkin H Lessner R Mann-Kaplan K Ramming HO Douglas P Thomas H Nave J Bateman J Lokich J Brooks J Chaffey JM Corson N Zamcheck JW. Novak Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (600 rads) radiation alone, moderate dose radiation (4000 rads 1 5-fluorouracil), and high dose radiation 5-fluorouracil Cancer 48 1981 1705 1710
174. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone J Natl Cancer Inst 80 1988 751 755
175. H Ishii S Okada K Tokuuye H Nose T Okusaka M Yoshimori H Nagahama M Sumi Y Kagami H. Ikeda Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma Cancer 79 1997 1516 1520
176. JM Robertson WD Ensminger S Walker TS. Lawrence A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer Int J Radiat Oncol Biol Phys 37 1997 331 335
177. G Boz A De Paoli M Roncadin G Franchin E Galligioni M Arcicasa R Bortolus C Gobitti E Minatel R Innocente MG. Trovo Radiation therapy combined with chemotherapy for inoperable pancreatic carcinoma Tumori 77 1991 61 64
178. H Safran TP King H Choy PJ Hesketh B Wolfe E Altenhein W Sikov A Rosmarin W Akerley K Radie-Keane G Cicchetti F Lopez K Bland HJ. Wanebo Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study J Clin Oncol 153 1997 901 907
179. TS Lawrence EY Chang TM Hahn LW Hertel DS. Shewach Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine Int J Radiat Oncol Biol Physiol 34 1996 867 872
180. GE Roldan LL Gunderson DM Nagorney JK Martin DM Ilstrup MA Holbrook LK Kvols DC. McIlrath External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer Cancer 61 1988 1110 1116
181. RR Dobelbower P. Montemaggi Brachytherapy for pancreatic cancer: a review Hepatogastroenterology 43 1996 333 337
182. A Raben B Mychalczak MF Brennan B Minsky L Anderson ES Casper LB. Harrison Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy Int J Radiat Oncol Biol Physiol 35 1996 351 356
183. PS Schein PT Lavin CG Moertel S Frytak RG Hahn MJ O'Connell RJ Reteimeier J Rubin AJ Schutt LH Weiland M Kalser J Barkin H Lessner R Mann-Kaplan D Redlhammer M Silverman M Troner HO Douglass S Milliron J Lokich J Brooks J Chaffe A Like N Zamchck K Ramming J Bateman H Spiro E Livstone A. Knowlton Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group report Cancer 42 1978 19 22
184. J Horton RD Gelber P Engstrom G Falkson C Moertel H Brodovsky H. Douglass Trials of a single-agent and combination chemotherapy for advanced cancer of the pancreas Cancer Treat Rep 65 1981 65 68
185. C Frey P Twomey R Keehn D Elliott G. Higgins Randomized study of 5-FU and CCNU in pancreatic cancer Cancer 47 1981 27 31
186. A Andren-Sandberg JT Holmberg I. Ihse Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine and CCNU Scand J Gastroenterol 18 1983 609 612
187. RM Bukowski SP Balcerzak RM O?Bryan JD Bonnet TT. Chen Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer Cancer 52 1983 1577 1582
188. Gastrointestinal Tumor Study Group Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas Cancer Treat Rep 69 1985 417 420
189. Gastrointestinal Tumor Study Group Phase II trials of single agents Baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer Cancer Treat Rep 71 1987 865 867
190. JJ Keating PJ Johnson AMG Cochrane BG Gazzard N Krasner PM Smith PN Trewby P Wheeler SP Wilkinson R. Williams A prospective randomized trial of tamoxifen and cyproterone acetate in pancreatic carcinoma Br J Cancer 60 1989 789 792
191. D Kelsen C Hudis D Niedzwiecki J Dougherty E Casper J Botet V Vinciguerra R. Rosenbluth A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma Cancer 68 1991 965 969
192. M Huguier G Samama J Testart S Mauban A Fingerhut J Nassar S Houry D Jaeck P De Mestier JO Favre F Michot A Vidrequin G Mantion M Veyrieres G Fourtanier P Lointier M. Gignoux Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (leuteinizing hormone-releasing hormone) Am J Surg 164 1992 348 353
193. RM Bukowski TR Fleming JS MacDonald N Oishi SA Taylor LH. Baker Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study Cancer 71 1993 322 325
194. RF Ashbury A Cnaan L Johnson J Harris SD Zaentz DG. Haller An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer Am J Clin Oncol 17 1994 166 169
195. MH Kalser SS. Ellenberg Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 1985 899 903